Current animal models of bladder cancer: Awareness of translatability (Review)

Experimental and Therapeutic Medicine

Volumn 8, Issue 3, 2014, Pages 691-699

  Ding, Jie ^a   Xu, Ding ^a   Pan, Chunwu ^a   Ye, Min ^a   Kang, Jian ^a   Bai, Qiang ^a   Qi, Jun ^a  

^a XINHUA HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Animal model; Bladder cancer; Carcinogen induced; Genetically engineered mouse; Translatability

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; BCG VACCINE; CARCINOGEN; CELECOXIB; DOXORUBICIN; HISTONE DEACETYLASE INHIBITOR; INDOMETACIN; METHYLNITROSOUREA; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; RAPAMYCIN; ROFECOXIB; UROPLAKIN 2;

ARTICLE; BLADDER CANCER; CLINICAL TRIAL (TOPIC); CYSTOSCOPY; DISEASE MODEL; GENE EXPRESSION; GENETICALLY ENGINEERED MOUSE STRAIN; HETEROTOPIC MODEL; HUMAN; MOUSE; NONHUMAN; ORTHOTOPIC MODEL; PLOIDY; RAT; RODENT; SQUAMOUS CELL CARCINOMA; SYNGENEIC MODEL; TRANSGENIC ORGANISM; TRANSITIONAL CELL CARCINOMA; TUMOR GROWTH; TUMOR MICROENVIRONMENT; XENOGENEIC MODEL;

EID: 84904387531     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2014.1837     Document Type: Article

References (134)

1. Siegel R, Naishadham D and Jemal A: Cancer statistics. CA Cancer J Clin 63: 11-30, 2013.
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J and Thun MJ: Cancer statistics. CA Cancer J Clin 59: 225-249, 2009.
3. Kroft SH and Oyasu R: Urinary bladder cancer: mechanisms of development and progression. Lab Invest 71: 158-174, 1994.
4. Knowles MA: What we could do now: molecular pathology of bladder cancer. Mol Pathol 54: 215-221, 2001.
5. Williams SG and Stein JP: Molecular pathways in bladder cancer. Urol Res 32: 373-385, 2004.
6. Spiess PE and Czerniak B: Dual-track pathway of bladder carcinogenesis: practical implications. Arch Pathol Lab Med 130: 844-852, 2006.
7. Wu XR: Urothelial tumorigenesis: a tale of divergent pathways. Nat Rev Cancer 5: 713-725, 2005.
8. Hoffman RM: The three-dimensional question: can clinically relevant tumor drug resistance be measured in vitro? Cancer Metastasis Rev 13: 169-173, 1994.
9. Yen WC, Schmittgen T and Au JL: Different pH dependency of mitomycin C activity in monolayer and three-dimensional cultures. Pharm Res 13: 1887-1891, 1996.
10. Fujiyama C, Jones A, Fuggle S, et al: Human bladder cancer invasion model using rat bladder in vitro and its use to test mechanisms and therapeutic inhibitors of invasion. Br J Cancer 84: 558-564, 2001.
11. Booth C, Harnden P, Trejdosiewicz LK, Scriven S, Selby PJ and Southgate J: Stromal and vascular invasion in an human in vitro bladder cancer model. Lab Invest 76: 843-857, 1997.
12. Sabbagh W, Masters JR, Duffy PG, et al: In vitro assessment of a collagen sponge for engineering urothelial grafts. Br J Urol 82: 888-894, 1998.
13. Verbridge SS, Choi NW, Zheng Y, Brooks DJ, Stroock AD and Fischbach C: Oxygen-controlled three-dimensional cultures to analyze tumor angiogenesis. Tissue Eng Part A 16: 2133-2141, 2010.
14. Oyasu R: Epithelial tumours of the lower urinary tract in humans and rodents. Food Chem Toxicol 33: 747-755, 1995.
15. Lindblad-Toh K: Genome sequencing: three's company. Nature 428: 475-476, 2004.
16. Russell PJ, Raghavan D, Gregory P, et al: Bladder cancer xenografts: a model of tumor cell heterogeneity. Cancer Res 46: 2035-2040, 1986.
17. Flanagan SP: 'Nude', a new hairless gene with pleiotropic effects in the mouse. Genet Res 8: 295-309, 1966.
18. Masters JR, Hepburn PJ, Walker L, et al: Tissue culture model of transitional cell carcinoma: characterization of twenty-two human urothelial cell lines. Cancer Res 46: 3630-3636, 1986.
19. Günther JH, Jurczok A, Wulf T, et al: Optimizing syngeneic orthotopic murine bladder cancer (MB49). Cancer Res 59: 2834-2837, 1999.
20. Hoffman RM: Orthotopic metastatic mouse models for anticancer drug discovery and evaluation: a bridge to the clinic. Invest New Drugs 17: 343-359, 1999.
21. Booth C, Harnden P, Selby PJ and Southgate J: Towards defining roles and relationships for tenascin-C and TGFbeta-1 in the normal and neoplastic urinary bladder. J Pathol 198: 359-368, 2002.
22. Reznikoff CA, Belair C, Savelieva E, et al: Long-term genome stability and minimal genotypic and phenotypic alterations in HPV16 E7-, but not E6-, immortalized human uroepithelial cells. Genes Dev 8: 2227-2240, 1994.
23. Kao C, Wu SQ, Bhatthacharya M, Meisner LF and Reznikoff CA: Losses of 3p, 11p, and 13q in EJ/ras-transformable simian virus 40-immortalized human uroepithelial cells. Genes Chromosomes Cancer 4: 158-168, 1992.
24. Harding MA, Arden KC, Gildea JW, et al: Functional genomic comparison of lineage-related human bladder cancer cell lines with differing tumorigenic and metastatic potentials by spectral karyotyping, comparative genomic hybridization, and a novel method of positional expression profiling. Cancer Res 62: 6981-6989, 2002.
25. Gildea JJ, Golden WL, Harding MA and Theodorescu D: Genetic and phenotypic changes associated with the acquisition of tumorigenicity in human bladder cancer. Genes Chromosomes Cancer 27: 252-263, 2000.
26. Cristofalo VJ, Lorenzini A, Allen RG, Torres C and Tresini M: Replicative senescence: a critical review. Mech Ageing Dev 125: 827-848, 2004.
27. Zhao L, Zhang ZY and Tong TJ: Systemic aging and replicative senescence: in vivo and in vitro. Sheng Li Ke Xue Jin Zhan 31: 205-210, 2000 (In Chinese).
28. MacLeod RAF, Dirks WG, Matsuo Y, et al: Widespread intraspecies cross-contamination of human tumor cell lines arising at source. Int J Cancer 83: 555-563, 1999.
29. Russell PJ, Raghavan D, Gregory P, et al: Bladder cancer xenografts: a model of tumor cell heterogeneity. Cancer Res 46: 2035-2040, 1986.
30. Davis DW, Inoue K, Dinney CP, Hicklin DJ, Abbruzzese JL and McConkey DJ: Regional effects of an antivascular endothelial growth factor receptor monoclonal antibody on receptor phosphorylation and apoptosis in human 253J B-V bladder cancer xenografts. Cancer Res 64: 4601-4610, 2004.
31. Inoue K, Slaton JW, Davis DW, et al: Treatment of human metastatic transitional cell carcinoma of the bladder in a murine model with the anti-vascular endothelial growth factor receptor monoclonal antibody DC101 and paclitaxel. Clin Cancer Res 6: 2635-2643, 2000.
32. Pfost B, Seidl C, Autenrieth M, et al: Intravesical alpha-radioimmunotherapy with 213Bi-anti-EGFR-mAb defeats human bladder carcinoma in xenografted nude mice. J Nucl Med 50: 1700-1708, 2009.
33. Makhlin I, Zhang J, Long CJ, et al: The mTOR pathway affects proliferation and chemosensitivity of urothelial carcinoma cells and is upregulated in a subset of human bladder cancers. BJU Int 108: E84-90, 2011.
34. Dinney CP, Fishbeck R, Singh RK, et al: Isolation and characterization of metastatic variants from human transitional cell carcinoma passaged by orthotopic implantation in athymic nude mice. J Urol 154: 1532-1538, 1995.
35. Soloway MS, Martino C, Hyatt C and Marrone JC: Immunogenicity of N-[-4-(5-nitro-2-furyl)-2-thiazolyl]formamide-induced bladder cancer. Natl Cancer Inst Monogr 293-300, 1978.
36. Soloway MS: Intravesical and systemic chemotherapy of murine bladder cancer. Cancer Res 37: 2918-2929, 1977.
37. Summerhayes IC and Franks LM: Effects of donor age on neoplastic transformation of adult mouse bladder epithelium in vitro. J Natl Cancer Inst 62: 1017-1023, 1979.
38. van Moorselaar RJ, Ichikawa T, Schaafsma HE, et al: The rat bladder tumor model system RBT resembles phenotypically and cytogenetically human superficial transitional cell carcinoma. Urol Res 21: 413-421, 1993.
39. Moltedo B, Faunes F, Haussmann D, et al: Immunotherapeutic effect of Concholepas hemocyanin in the murine bladder cancer model: evidence for conserved antitumor properties among hemocyanins. J Urol 176: 2690-2695, 2006.
40. Bisson JF, Parache RM, Droulle P, Notter D, Vigneron C and Guillemin F: A new method of implanting orthotopic rat bladder tumor for experimental therapies. Int J Cancer 102: 280-285, 2002.
41. Hanel EG, Xiao Z, Wong KK, Lee PW, Britten RA and Moore RB: A novel intravesical therapy for superficial bladder cancer in an orthotopic model: oncolytic reovirus therapy. J Urol 172: 2018-2022, 2004.
42. Fodor I, Timiryasova T, Denes B, Yoshida J, Ruckle H and Lilly M: Vaccinia virus mediated p53 gene therapy for bladder cancer in an orthotopic murine model. J Urol 173: 604-609, 2005.
43. Loskog AS, Fransson ME and Totterman TT: AdCD40L gene therapy counteracts T regulatory cells and cures aggressive tumors in an orthotopic bladder cancer model. Clin Cancer Res 11: 8816-8821, 2005.
44. Kuromatsu I, Matsuo K, Takamura S, et al: Induction of effective antitumor immune responses in a mouse bladder tumor model by using DNA of an alpha antigen from mycobacteria. Cancer Gene Ther 8: 483-490, 2001.
45. Miyazaki J, Nishiyama H, Yano I, et al: The therapeutic effects of R8-liposome-BCG-CWS on BBN-induced rat urinary bladder carcinoma. Anticancer Res 31: 2065-2071, 2011.
46. Smaldone MC, Gayed BA, Tomaszewski JJ and Gingrich JR: Strategies to enhance the efficacy of intravescical therapy for non-muscle invasive bladder cancer. Minerva Urol Nefrol 61: 71-89, 2009.
47. Smaldone MC, Gayed BA, Tomaszewski JJ and Gingrich JR: Strategies to enhance the efficacy of intravescical therapy for non-muscle invasive bladder cancer. Minerva Urol Nefrol 61: 71-89, 2009.
48. Shen ZJ, Wang Y, Ding GQ, Pan CW and Zheng RM: Study on enhancement of fibronectin-mediated bacillus Calmette-Guérin attachment to urinary bladder wall in rabbits. World J Urol 25: 525-529, 2007.
49. Günther JH, Frambach M, Deinert I, Brandau S, Jocham D and Böhle A: Effects of acetylic salicylic acid and pentoxifylline on the efficacy of intravesical BCG therapy in orthotopic murine bladder cancer (MB49). J Urol 161: 1702-1706, 1999.
50. Reis LO, Ferreira U, Billis A, Cagnon VH and Fávaro WJ: Anti-angiogenic effects of the superantigen staphylococcal enterotoxin B and bacillus Calmette-Guérin immunotherapy for nonmuscle invasive bladder cancer. J Urol 187: 438-445, 2012.
51. Talmadge JE, Singh RK, Fidler IJ and Raz A: Murine models to evaluate novel and conventional therapeutic strategies for cancer. Am J Pathol 170: 793-804, 2007.
52. Lodillinsky C, Rodriguez V, Vauthay L, Sandes E, Casabé A and Eiján AM: Novel invasive orthotopic bladder cancer model with high cathepsin B activity resembling human bladder cancer. J Urol 182: 749-755, 2009.
53. Black PC and Dinney CP: Bladder cancer angiogenesis and metastasis-translation from murine model to clinical trial. Cancer Metastasis Rev 26: 623-634, 2007.
54. Wilmanns C, Fan D, Obrian C, et al: Modulation of Doxorubicin sensitivity and level of p-glycoprotein expression in human colon-carcinoma cells by ectopic and orthotopic environments in nude-mice. Int J Oncol 3: 413-422, 1993.
55. Bibby MC: Orthotopic models of cancer for preclinical drug evaluation: advantages and disadvantages. Eur J Cancer 40: 852-857, 2004.
56. Zhang Z, Xu X, Zhang X, et al: The therapeutic potential of SA-sCD40L in the orthotopic model of superficial bladder cancer. Acta Oncol 50: 1111-1118, 2011.
57. Xiao Z, McCallum TJ, Brown KM, et al: Characterization of a novel transplantable orthotopic rat bladder transitional cell tumour model. Br J Cancer 81: 638-646, 1999.
58. Chade DC, Andrade PM, Borra RC, et al: Histopathological characterization of a syngeneic orthotopic murine bladder cancer model. Int Braz J Urol 34: 220-226; discussion 226-229, 2008.
59. Jiang F and Zhou XM: A model of orthotopic murine bladder (MBT-2) tumor implants. Urol Res 25: 179-182, 1997.
60. Romih R, Jezernik K and Masera A: Uroplakins and cytokeratins in the regenerating rat urothelium after sodium saccharin treatment. Histochem Cell Biol 109: 263-269, 1998.
61. Gabriel U, Bolenz C and Michel MS: Experimental models for therapeutic studies of transitional cell carcinoma. Anticancer Res 27: 3163-3171, 2007.
62. Oshinsky GS, Chen Y, Jarrett T, Anderson AE and Weiss GH: A model of bladder tumor xenografts in the nude rat. J Urol 154: 1925-1929, 1995.
63. Watanabe T, Shinohara N, Sazawa A, et al: An improved intravesical model using human bladder cancer cell lines to optimize gene and other therapies. Cancer Gene Ther 7: 1575-1580, 2000.
64. Asanuma H, Arai T, Seguchi K, et al: Successful diagnosis of orthotopic rat superficial bladder tumor model by ultrathin cystoscopy. J Urol 169: 718-720, 2003.
65. Hendricksen K, Molkenboer-Kuenen J, Oosterwijk E, Hulsbergen-van de Kaa CA and Witjes JA: Evaluation of an orthotopic rat bladder urothelial cell carcinoma model by cystoscopy. BJU Int 101: 889-893, 2008.
66. Nokes B, Apel M, Jones C, Brown G and Lang JE: Aminolevulinic acid (ALA): photodynamic detection and potential therapeutic applications. J Surg Res 181: 262-271, 2013.
67. Satoh H, Morimoto Y, Arai T, et al: Intravesical ultrasonography for tumor staging in an orthotopically implanted rat model of bladder cancer. J Urol 177: 1169-1173, 2007.
68. Chin J, Kadhim S, Garcia B, Kim YS and Karlik S: Magnetic resonance imaging for detecting and treatment monitoring of orthotopic murine bladder tumor implants. J Urol 145: 1297-1301, 1991.
69. Kikuchi E, Xu S, Ohori M, et al: Detection and quantitative analysis of early stage orthotopic murine bladder tumor using in vivo magnetic resonance imaging. J Urol 170: 1375-1378, 2003.
70. Becci PJ, Thompson HJ, Strum JM, Brown CC, Sporn MB and Moon RC: N-butyl-N-(4-hydroxybutyl)nitrosamine-induced urinary bladder cancer in C57BL/6 X DBA/2 F1 mice as a useful model for study of chemoprevention of cancer with retinoids. Cancer Res 41: 927-932, 1981.
71. Cohen SM and Johansson SL: Epidemiology and etiology of bladder cancer. Urol Clin North Am 19: 421-428, 1992.
72. Yamagiwa K and Ichikawa K: Experimental study of the pathogenesis of carcinoma. CA Cancer J Clin 27: 174-181, 1977.
73. Hueper WC, Wiley FH, Wolfe HD, et al: Experimental production of bladder tumors in dogs by administration of beta-naphthylamine. J Ind Hyg Toxicol 20: 46-84, 1938.
74. Armstrong EC and Bonser GM: Epithelial tumours of the urinary bladder in mice induced by 2-acetylamino-fluorine. J Pathol 6: 506-512, 1944.
75. Schalken JA, van Moorselaar RJ, Bringuier PP and Debruyne FM: Critical review of the models to study the biologic progression of bladder cancer. Semin Surg Oncol 8: 274-278, 1992.
76. Oliveira PA, Colaco A, De la Cruz P LF and Lopes C: Experimental bladder carcinogenesis-rodent models. Exp Oncol 28: 2-11, 2006.
77. Clayson DB and Cooper EH: Cancer of the urinary tract. Adv Cancer Res 13: 271-381, 1970.
78. Fukushima S: Modification of tumor development in the urinary bladder. Prog Exp Tumor Res 33: 154-174, 1991.
79. Kunze E and Chowaniec J: Pathology of tumours in laboratory animals. Tumours of the rat. Tumours of the urinary bladder. IARC Sci Publ: 345-397, 1990.
80. Oliveira PA, Palmeira C, Lourenço LM and Lopes CA: Evaluation of DNA content in preneoplastic changes of mouse urinary bladder induced by N-butyl-N-(4-hydroxybutyl) nitrosamine. J Exp Clin Cancer Res 24: 609-616, 2005.
81. Lu Y, Liu P, Wen W, et al: Cross-species comparison of orthologous gene expression in human bladder cancer and carcinogen-induced rodent models. Am J Transl Res 3: 8-27, 2010.
82. Cauvin JM, Goldfain D, Le Rhun M, et al: Multicentre prospective controlled study of Barrett's oesophagus and colorectal adenomas. Groupe d'Etude de l'Oesophage de Barrett. Lancet 346: 1391-1394, 1995.
83. Castelao JE, Yuan JM, Gago-Dominguez M, Yu MC and Ross RK: Non-steroidal anti-inflammatory drugs and bladder cancer prevention. Br J Cancer 82: 1364-1369, 2000.
84. Grubbs CJ, Lubet RA, Koki AT, et al: Celecoxib inhibits N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder cancers in male B6D2F1 mice and female Fischer-344 rats. Cancer Res 60: 5599-5602, 2000.
85. Steele VE, Rao CV, Zhang Y, et al: Chemopreventive efficacy of naproxen and nitric oxide-naproxen in rodent models of colon, urinary bladder, and mammary cancers. Cancer Prev Res (Phila) 2: 951-956, 2009.
86. Lubet RA, Huebner K, Fong LY, et al: 4-Hydroxybutyl(butyl)nitrosamine-induced urinary bladder cancers in mice: characterization of FHIT and survivin expression and chemopreventive effects of indomethacin. Carcinogenesis 26: 571-578, 2005.
87. Okajima E, Denda A, Ozono S, et al: Chemopreventive effects of nimesulide, a selective cyclooxygenase-2 inhibitor, on the development of rat urinary bladder carcinomas initiated by N-butyl-N-(4-hydroxybutyl)nitrosamine. Cancer Res 58: 3028-3031, 1998.
88. Hattori K, Iida K, Joraku A, Tsukamoto S, Akaza H and Oyasu R: Chemopreventive effects of cyclooxygenase-2 inhibitor and epidermal growth factor-receptor kinase inhibitor on rat urinary bladder carcinogenesis. BJU Int 97: 640-643, 2006.
89. D'Arca D, LeNoir J, Wildemore B, et al: Prevention of urinary bladder cancer in the FHIT knock-out mouse with Rofecoxib, a Cox-2 inhibitor. Urol Oncol 28: 189-194, 2010.
90. Ozawa A, Tanji N, Kikugawa T, et al: Inhibition of bladder tumour growth by histone deacetylase inhibitor. BJU Int 105: 1181-1186, 2010.
91. Ding Y, Paonessa JD, Randall KL, et al: Sulforaphane inhibits 4-aminobiphenyl-induced DNA damage in bladder cells and tissues. Carcinogenesis 31: 1999-2003, 2010.
92. Parada B, Reis F, Figueiredo A, et al: Inhibition of bladder tumour growth by sirolimus in an experimental carcinogenesis model. BJU Int 107: 135-143, 2011.
93. Parada B, Reis F, Pinto A, et al: Chemopreventive efficacy of atorvastatin against nitrosamine-induced rat bladder cancer: antioxidant, anti-proliferative and anti-inflammatory properties. Int J Mol Sci 13: 8482-8499, 2012.
94. Sagara Y, Miyata Y, Nomata K, Hayashi T and Kanetake H: Green tea polyphenol suppresses tumor invasion and angiogenesis in N-butyl-(-4-hydroxybutyl) nitrosamine-induced bladder cancer. Cancer Epidemiol 34: 350-354, 2010.
95. Prasain JK, Jones K, Moore R, et al: Effect of cranberry juice concentrate on chemically-induced urinary bladder cancers. Oncol Rep 19: 1565-1570, 2008.
96. Zhang G, Zeng X, Li C, et al: Inhibition of urinary bladder carcinogenesis by aqueous extract of sclerotia of Polyporus umbellatus fries and polyporus polysaccharide. Am J Chin Med 39: 135-144, 2011.
97. Munday R, Mhawech-Fauceglia P, Munday CM, et al: Inhibition of urinary bladder carcinogenesis by broccoli sprouts. Cancer Res 68: 1593-1600, 2008.
98. Kunze E, Schulz H, Adamek M and Gabius HJ: Long-term administration of galactoside-specific mistletoe lectin in an animal model: no protection against N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder carcinogenesis in rats and no induction of a relevant local cellular immune response. J Cancer Res Clin Oncol 126: 125-138, 2000.
99. Fukushima S, Hirose M, Tsuda H, Shirai T and Hirao K: Histological classification of urinary bladder cancers in rats induced by N-butyl-n-(4-hydroxybutyl)nitrosamine. Gann 67: 81-90, 1976.
100. Becci PJ, Thompson HJ, Strum JM, et al: N-butyl-N-(4-hydroxybutyl) nitrosamine-induced urinary bladder cancer in C57BL/6 X DBA/2 F1 mice as a useful model for study of chemoprevention of cancer with retinoids. Cancer Res 41: 927-932, 1981.
101. Herman CJ, Vegt PD, Debruyne FM, Vooijs GP and Ramaekers FC: Squamous and transitional elements in rat bladder carcinomas induced by N-butyl-N-4-hydroxybutyl-nitrosamine (BBN). A study of cytokeratin expression. Am J Pathol 120: 419-426, 1985.
102. Hicks RM and Wakefield JS: Rapid induction of bladder cancer in rats with N-methyl-N-nitrosourea. I. Histology. Chem Biol Interact 5: 139-152, 1972.
103. Steinberg GD, Brendler CB, Ichikawa T, Squire RA and Isaacs JT: Characterization of an N-methyl-N-nitrosourea-induced autochthonous rat bladder cancer model. Cancer Res 50: 6668-6674, 1990.
104. Russo J, Russo IH, Rogers AE, van Zwieten MJ and Gusterson B: Pathology of tumours in laboratory animals. Tumours of the rat. Tumours of the mammary gland. IARC Sci Publ: 47-78, 1990.
105. Wu JT, Han BM, Yu SQ, Wang HP and Xia SJ: Androgen receptor is a potential therapeutic target for bladder cancer. Urology 75: 820-827, 2010.
106. Li Y, Zheng Y, Izumi K, et al: Androgen activates beta-catenin signaling in bladder cancer cells. Endocr Relat Cancer 20: 293-304, 2013.
107. Kunze E, Graewe T, Scherber S, Weber J and Gellhar P: Cell cycle dependence of N-methyl-N-nitrosourea-induced tumour development in the proliferating, partially resected rat urinary bladder. Br J Exp Pathol 70: 125-142, 1989.
108. Tian B, Wang Z, Zhao Y, et al: Effects of curcumin on bladder cancer cells and development of urothelial tumors in a rat bladder carcinogenesis model. Cancer Lett 264: 299-308, 2008.
109. Fragoso MF, Prado MG, Barbosa L, Rocha NS and Barbisan LF: Inhibition of mouse urinary bladder carcinogenesis by açai fruit (Euterpe oleraceae Martius) intake. Plant Foods Hum Nutr 67: 235-241, 2012.
110. Bidinotto LT, Spinardi-Barbisan AL, Rocha NS, Salvadori DM and Barbisan LF: Effects of ginger (Zingiber officinale Roscoe) on DNA damage and development of urothelial tumors in a mouse bladder carcinogenesis model. Environ Mol Mutagen 47: 624-630, 2006.
111. Jaenisch R and Mintz B: Simian virus 40 DNA sequences in DNA of healthy adult mice derived from preimplantation blastocysts injected with viral DNA. Proc Natl Acad Sci USA 71: 1250-1254, 1974.
112. Hanahan D, Wagner EF and Palmiter RD: The origins of oncomice: a history of the first transgenic mice genetically engineered to develop cancer. Genes Dev 21: 2258-2270, 2007.
113. Lin JH, Zhao H and Sun TT: A tissue-specific promoter that can drive a foreign gene to express in the suprabasal urothelial cells of transgenic mice. Proc Natl Acad Sci USA 92: 679-683, 1995.
114. Zhang ZT, Pak J, Shapiro E, Sun TT and Wu XR: Urothelium-specific expression of an oncogene in transgenic mice induced the formation of carcinoma in situ and invasive transitional cell carcinoma. Cancer Res 59: 3512-3517, 1999.
115. Grippo PJ and Sandgren EP: Highly invasive transitional cell carcinoma of the bladder in a simian virus 40 T-antigen transgenic mouse model. Am J Pathol 157: 805-813, 2000.
116. Koss LG: Bladder cancer from a perspective of 40 years. J Cell Biochem Suppl 16I: 23-29, 1992.
117. Zhang ZT, Pak J, Huang HY, et al: Role of Ha-ras activation in superficial papillary pathway of urothelial tumor formation. Oncogene 20: 1973-1980, 2001.
118. Jebar AH, Hurst CD, Tomlinson DC, Johnston C, Taylor CF and Knowles MA: FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma. Oncogene 24: 5218-5225, 2005.
119. Kompier LC, Lurkin I, van der Aa MN, van Rhijn BW, van der Kwast TH and Zwarthoff EC: FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy. PLoS One 5: e13821, 2010.
120. Cheng J, Huang H, Zhang ZT, et al: Overexpression of epidermal growth factor receptor in urothelium elicits urothelial hyperplasia and promotes bladder tumor growth. Cancer Res 62: 4157-4163, 2002.
121. Lindgren D, Liedberg F, Andersson A, et al: Molecular characterization of early-stage bladder carcinomas by expression profiles, FGFR3 mutation status, and loss of 9q. Oncogene 25: 2685-2696, 2006.
122. Puzio-Kuter AM, Castillo-Martin M, Kinkade CW, et al: Inactivation of p53 and Pten promotes invasive bladder cancer. Genes Dev 23: 675-680, 2009.
123. Ayala de la Peña F, Kanasaki K, Kanasaki M, Tangirala N, Maeda G and Kalluri R: Loss of p53 and acquisition of angiogenic microRNA profile are insufficient to facilitate progression of bladder urothelial carcinoma in situ to invasive carcinoma. J Biol Chem 286: 20778-20787, 2011.
124. Ho PL, Lay EJ, Jian W, Parra D and Chan KS: Stat3 activation in urothelial stem cells leads to direct progression to invasive bladder cancer. Cancer Res 72: 3135-3142, 2012.
125. Ogawa K, Murasaki T, Sugiura S, Nakanishi M and Shirai T: Organ differences in the impact of p27(kip1) deficiency on carcinogenesis induced by N-methyl-N-nitrosourea. J Appl Toxicol 33: 471-479, 2013.
126. Baffa R, Fassan M, Sevignani C, et al: Fez1/Lzts1-deficient mice are more susceptible to N-butyl-N-(4-hydroxybutil) nitrosamine (BBN) carcinogenesis. Carcinogenesis 29: 846-848, 2008.
127. Slocum SL and Kensler TW: Nrf2: control of sensitivity to carcinogens. Arch Toxicol 85: 273-284, 2011.
128. Fukushima S, Friedell GH, Jacobs JB and Cohen SM: Effect of L-tryptophan and sodium saccharin on urinary tract carcinogenesis initiated by N-[4-(5-nitro-2-furyl)-2-thiazolyl]formamide. Cancer Res 41: 3100-3103, 1981.
129. Gibbs RA, Weinstock GM, Metzker ML, et al; Rat Genome Sequencing Project Consortium: Genome sequence of the Brown Norway rat yields insights into mammalian evolution. Nature 428: 493-521, 2004.
130. Mouse Genome Sequencing Consortium, Waterston RH, Lindblad-Toh K, et al: Initial sequencing and comparative analysis of the mouse genome. Nature 420: 520-562, 2002.
131. Kitada K, Ishishita S, Tosaka K, et al: Transposon-tagged mutagenesis in the rat. Nat Methods 4: 131-133, 2007.
132. Geurts AM, Cost GJ, Freyvert Y, et al: Knockout rats via embryo microinjection of zinc-finger nucleases. Science 325: 433, 2009.
133. Corpet DE and Pierre F: How good are rodent models of carcinogenesis in predicting efficacy in humans? A systematic review and meta-analysis of colon chemoprevention in rats, mice and men. Eur J Cancer 41: 1911-1922, 2005.
134. Zeng J, Sun Y, Wu K, et al: Chemopreventive and chemotherapeutic effects of intravesical silibinin against bladder cancer by acting on mitochondria. Mol Cancer Ther 10: 104-116, 2011.